PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2117027
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2117027
Insufflation Devices Market size was valued at US$ 3,180.7 Million in 2025, expanding at a CAGR of 6.1% from 2026 to 2033.
Insufflation devices produce and control the flow of carbon dioxide to create an operative cavity and maintain it throughout the minimally invasive procedure. These devices consist of pressure regulators, filters, tubes, smoke evacuation systems, heated and humidification, and other accessories. The devices are primarily used in hospitals and surgery centers for minimally invasive procedures, including robot-assisted surgeries, but not in dental practices. The industry trend is shifting from simple insufflation devices to advanced platforms that allow for maintaining performance-led insufflation during suction and provide enhanced visualization of the surgical site. According to the CONMED press release from 2025, AirSeal has been used in nearly 8 million procedures in 5,857 facilities across 82 countries. Thus, it can be stated that the company has an excellent opportunity to promote its products on a global scale by leveraging the growing demand for sophisticated devices for maintaining performance-led insufflation.
Insufflation Devices Market- Market Dynamics
Clinical Validation Elevates Low-Pressure Insufflation
Stable pneumoperitoneum is becoming a critical factor in the development of the procedure since the loss of suction or the exodus of gas during the introduction of instruments can lead to reduced vision and performance. These systems can provide the required gas barrier, compensate for pressure, remove smoke, and work under low-pressure conditions, which allows for a change in the paradigm from the purchasing department. Procurement is now based on specific performance-related criteria instead of theoretical flow rates. CONMED revealed in 2025 that evidence from AirSeal was present in 38 peer-reviewed publications across seven surgical specialties, including low-pressure insufflation positionality. Overall, the trend shows that clinical evidence is becoming an essential purchasing criterion in the global minimally invasive surgery field, which spans an extensive range of robotic and laparoscopic procedures.
The Global Insufflation Devices Market is segmented on the basis of Product Type, Application, End User, and Region.
Under product type category, Insufflators occupy the dominant market share owing to their being the essential equipment used to develop and sustain the pneumoperitoneum during minimally invasive surgeries. Their usage is expected to increase owing to the growing popularity of laparoscopy and need for accurate pressure and flow control. The smoke evacuation and insufflation systems will grow at the fastest rate, as a result of rising attention towards surgical smoke management and OR safety. The US FDA keeps advising the use of smoke evacuation systems in cases where there is surgical smoke production, thus favoring the adoption of smoke evacuation systems with reliable insufflation capabilities.
In terms of application segment, the laparoscopy surgery segment is projected to continue being the leading one, driven by the widespread adoption of this procedure in various general, colorectal, gynecological, and urological procedures. According to the statistics from the World Health Organization, there are over 300 million major surgical operations being carried out every year in different parts of the world, providing a strong procedure base for minimally invasive techniques. Bariatric surgery is also forecast to be one of the segments experiencing the fastest growth rate, due to the growing rates of obesity and use of minimally invasive weight loss surgeries. There are forecasts that over 4 billion people will suffer from obesity or be overweight in 2035.
Insufflation Devices Market- Geographical Insights
A mature endoscopic surgery ecosystem, broad hospital networks, and medical device manufacturing hubs have made North America a key region for insufflation technologies. An increasing number of purchasing decisions are driven by the combination of robotic surgery, smoke management, and clinical staff considerations, favoring integrated solutions over standalone gas generators. This region can also serve as a platform for regulatory approvals and specialized channel sales. According to Intuitive's reports, their devices were already installed in over 12,000 surgical and interventional systems worldwide as of 2025. This represents a major installed base end-surgery market penetration in terms of compatible insufflation systems and can generate significant sales across North America's leading hospitals and surgical centers.
The European market is similarly poised to benefit from the convergence of minimally invasive surgery, advanced medical device regulation, and the presence of major endoscopy and surgery medical device manufacturers. These dynamics make it natural for European hospitals to approach buying decisions from the perspective of combined visualization, smoke management, gas management, ergonomics, and regulatory compliance. At the same time, local distributors benefit from the proximity to leading clinical facilities and surgical centers. According to Olympus's own reports, the organization employs 29,297 people worldwide as of March 2025. This broad organizational footprint, spanning numerous countries and thousands of employees, allows the company to better address the needs of the surgical technology market and contribute to the regional differentiation of its insufflation products.
Competition trends toward integrated surgical platforms in which insufflation is differentiated by pressure maintenance, smoke evacuation, gas conditioning, robotic compatibility, clinical evidence, and service. CONMED highlights the low-pressure design of AirSeal and its clinical evidence, while KARL STORZ focuses on the combination of insufflation with smoke evacuation, desufflation, heating, and humidification. Intuitive increasingly ties insufflation to robotic-assisted surgery, and interoperability is a strategic consideration for suppliers. In 2025, Intuitive reported that over 1,200 da Vinci 5 systems had been installed in the United States, Korea, Japan, and Europe and that these systems had been used in more than 270,000 procedures. A competitive advantage was gained by virtue of the ecosystem in which the devices were offered rather than by individual attributes.
In April 2025, KARL STORZ presented the ENDOFLATOR+ insufflation device with integrated smoke evacuation, heated and humidified gas, and multiple procedure functions. The smoke evacuation technology of ENDOFLATOR+ filters out 99.9% of particulates from tests, providing improved safety for the surgical team and greater visibility during procedures.
In October 2025, KARL STORZ received U.S. FDA clearance for ENDOFLATOR+ for its integrated capabilities as an insufflator and smoke-evacuation system. ENDOFLATOR+ provides suction and insufflation with heated or humidified gas and multiple procedure options for a variety of surgical specialties.